Teva Soars 17% In Pre-Market - No Dividend, No Workers, No Problems
Investors are panic-buying Israeli generic drugmaker Teva Pharmaceutical after the new CEO announces restructuring plan that involves eliminating 25% of global workforce, suspending its dividend, and warns of "downward pressure on the top line." As WSJ reports, Teva Pharmaceutical is cutting more
...Далее